First-Line Treatment of Bone Metastases
When cancer spreads to bone, prompt initiation of bone-modifying therapy is recommended at the time of diagnosis — including in asymptomatic patients — and maintained throughout the course of disease to reduce the risk of skeletal-related events.
Clinical Situation
This protocol addresses first-line bone-protective management at the point of confirmed skeletal involvement, regardless of symptom status. Both intravenous and subcutaneous bone-modifying options are considered, alongside nutritional co-supplementation, initiated from diagnosis and continued on a long-term basis.
Treatment Approach
The regimen centres on bone-modifying agents — one delivered intravenously on a scheduled interval, and an alternative delivered subcutaneously — combined with supplemental support. Frequency of administration and the choice between agents depend on factors detailed in the full protocol.
The complete regimen — including agent selection, administration intervals, supplementation specifics, and continuation criteria — is available in the structured protocol below.
References
DOI: 10.1007/s12094-016-1590-1
- Zoledronate or zoledronic acid (ZA), the most effective third-generation bisphosphonate in preventing SRE, is administered at a dose of 4 mg intravenous (iv) during 15 min every 3 (q3w) or 4 weeks (q4w), with supplemental calcium and vitamin D.
- It is recommended to start at the bone metastases diagnosis, even the patient is asymptomatic, and should be continued indefinitely during the disease.
- Denosumab is recommended to be administered at a dose of 120 mg as a single subcutaneous (sc) injection once every 4 weeks taking supplemental calcium and vitamin D.
- It is recommended to start its use at the bone metastases diagnosis and should be continued indefinitely during the disease.
- The proportion of SRE was 29.5 vs 28.6% (p = 0.79) for monthly and every 3 months, respectively, showing that zoledronic administered every 3 months is non-inferior to zoledronic administered monthly for 24 months.
View source ↗